Precigen (NASDAQ:PGEN) Receives Market Outperform Rating from JMP Securities

JMP Securities restated their market outperform rating on shares of Precigen (NASDAQ:PGEN) in a research report sent to investors on Tuesday morning,Benzinga reports. JMP Securities currently has a $5.00 price target on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Precigen in a report on Friday, November 15th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $6.33.

Precigen Price Performance

Shares of PGEN opened at $1.09 on Tuesday. The stock has a market capitalization of $317.76 million, a PE ratio of -1.97 and a beta of 1.65. The business’s fifty day moving average price is $0.90 and its 200 day moving average price is $1.08. Precigen has a 12-month low of $0.65 and a 12-month high of $1.93.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of PGEN. Iridian Asset Management LLC CT boosted its position in shares of Precigen by 82.5% during the third quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock worth $3,576,000 after buying an additional 1,706,815 shares during the period. Geode Capital Management LLC boosted its position in Precigen by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after acquiring an additional 149,829 shares during the period. State Street Corp boosted its position in Precigen by 1.0% during the 3rd quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock worth $2,720,000 after acquiring an additional 29,253 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Precigen by 11.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock valued at $1,158,000 after purchasing an additional 127,467 shares during the period. Finally, Renaissance Technologies LLC raised its stake in shares of Precigen by 12.4% during the second quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company’s stock valued at $1,869,000 after purchasing an additional 130,500 shares in the last quarter. Institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.